Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia
Sleep Medicine · 2024
DOI: 10.1016/j.sleep.2024.09.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sleep Medicine, 2024. Verfasst von John W Winkelman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: jwwinkelman@m…. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Triazoles, Azepines, Restless Legs Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Schlaf
Abstract (Originalsprache)
BACKGROUND: Sleep disturbance remains common in people with Restless Legs Syndrome (RLS), even after RLS symptoms are sufficiently controlled with medication. We conducted a placebo-controlled crossover trial to examine the efficacy of suvorexant in improving sleep quality and quantity in people with well-controlled RLS and persistent insomnia. METHODS: In this double-blind, randomized, placebo-controlled crossover trial, 34 participants (70.6 % female, mean age = 62.7) with well-controlled RLS were randomized to placebo or suvorexant (10-20 mg) for 6 weeks, followed by a 2-week washout and then the opposite treatment. Study inclusion required an IRLS score 45 min and a Total Sleep Time (TST) < 7 h on 7/14 baseline nights. The primary outcome was actigraphically-derived TST, and secondary outcomes were Insomnia Severity Index (ISI) score and actigraphically-derived WASO. Data for all sleep metrics were collected at baseline and for the last two weeks of each treatment period. RESULTS: There were no significant improvements in actigraphically-derived TST (p = 0.58) or WASO (p = 0.99) while taking suvorexant compared to placebo. However, there were significant reductions in insomnia symptoms, measured by the ISI, as well as increases in diary-reported TST (p = 0.01) while taking suvorexant compared to placebo. The most commonly reported side effect of suvorexant was fatigue (29.4 %). CONCLUSIONS: We observed no significant differences between treatments in actigraphically-derived sleep measures, but support for suvorexant's benefit for overall insomnia and self-reported quantity of sleep in people with well-controlled RLS who continue to suffer from insomnia. CLINICAL TRIALS REGISTRATION NUMBER: NCT04706091.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: jwwinkelman@mgh.harvard.edu.
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address: jzackon@mgh.harvard.edu.
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. Electronic address: akilty@mgh.harvard.edu.
Zitieren
APA
Winkelman, J. W., Zackon, J., & Kilty, A. (2024). Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia. Sleep Medicine. https://doi.org/10.1016/j.sleep.2024.09.005
Vancouver
Winkelman JW, Zackon J, Kilty A. Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia. Sleep Medicine. 2024. doi:10.1016/j.sleep.2024.09.005
BibTeX
@article{Winkelman2024,
author = {Winkelman, John W and Zackon, Jordana and Kilty, Adysn},
title = {Improvement in self-reported, but not actigraphic, sleep measures with suvorexant in people with well-controlled Restless Legs Syndrome and persistent insomnia},
journal = {Sleep Medicine},
year = {2024},
doi = {10.1016/j.sleep.2024.09.005}
}
EUVIMED